Skip to main content
Sign In
 

Ivor S. Douglas, MD, FRCP (UK)


 



 

  University of Colorado Denver

  Ivor S. Douglas MD. FRCP(UK)

  Associate Professor

  Chief, Pulmonary Sciences & Critical Care
  Medicine Director, Medical Intensive Care
  Denver Health Medical Center

  Email: idouglas@dhha.org

 

 

Education & Training

1985 – 1990 MB BCh, Medical School Program, Witwatersrand, South Africa
1991 - 1992  Internship Medicine, Surgery, Critical Care, Johannesburg General  Hospital, South Africa
1992 - 1994  Senior Registrar, Thoracic & General Internal Medicine, King’s College Hospital & St. Thomas Hospital, London, UK
1994 - 1995  Research Associate Pulmonary, Critical Care; University of Chicago, Chicago, IL
1995 - 1997  Categorical Residency, Internal Medicine; University of Chicago, Chicago, IL
1997 - 2002  Research Pathway ABIM Fellowship, Pulmonary & Critical Care; University of Chicago, Chicago, IL & Columbia University, New York, NY
   
PROFESSIONAL EXPERIENCE

• Chief; Division of Pulmonary Sciences and Critical Care Medicine, Denver Health Medical Center
• Director, Medical Intensive Care Unit: Denver Health Medical Center.
• Co-Chair: Interdisciplinary Critical Care Committee. Denver Health Medical Center.
• NIH Study Sections: NHLBI Translational Research Implementation Program (TRIP) panel, ’09; NHLBI K01 "Mentored Career Development Awards ‘10
• Co-chair (2009 - present); International Surviving Sepsis Campaign.
• Editorial Board: CHEST; Faculty of 1000 Medicine;
• Peer Review: Journal of Clinical Investigation, Am. J. Resp. Crit Care Med. Am. J. Resp. Cell. Molecular Biol., PATS, Chest, Intensive Care Med, Critical Care Journal, Crit. Care Medicine.
• SCCM Chair: ICU Quality & Safety committee
• SCCM Principle to Hospital Quality Alliance (HQA): hospital quality reporting program; 2008-
• Am. Thoracic Society: Health policy, Crit. Care program and Critical Care planning committees.
• External Consultant: Paragon Critical Care Improvement - SCCM
• Physician Sponsor; CPOE, ICU clinical documentation &Toyota “Lean” MICU Value Stream.
• International Steering Committee and Co-PI; Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock (ASSURE)

Honors and Awards
• Merk Respiratory Young Investigator award 1998.
• Resident teacher award 1999, University of Chicago
• Junior faculty award for Resident Teaching 1999-2000, Columbia Student Teaching award 2000
• Faculty teaching award, 2003. Dept. of Medicine. U. Colorado
• CEO Commendation Award, Denver Health Medical Center, 2004 and 2006
• Chest Foundation Young Leadership Travel Award, 2005
• “Best Doctors”: 5280 Magazine, and Best Doctors in America, 2008,2009
• Elected Fellow, American College of Chest Physicians, 2005
• Elected Fellow, Royal College of Physicians, London UK, 2009 

Research Interests

 1. Lung Injury Repair and Remodeling

• Animal models of ALI repair and remodeling using cell/molecular biology techniques to explore the role of the Wnt-β-catenin signaling cascade in lung septal repair and remodeling.
• Animal models of repair and remodeling failure in emphysema using cell/molecular biology techniques to explore the role of the Wnt-β-catenin signaling cascade in lung septal repair and remodeling failure.
• The effects of regional ventilation on lung injury repair and remodeling. In vivo model of prolonged high volume ventilation in rats. (Focusing on MKP-1 mediated MAPK regulation in ALI)
• Studies Lipid A LPS mediated TLR4 dependent lung injury repair and remodeling

 2. Critical care clinical outcomes studies

• Clinical trials of novel therapeutic interventions for sepsis, ALI/ARDS and metabolic derangements of critical illness. PI- PROWESS SHOCK
• The effect of alcohol on outcomes from sepsis and respiratory failure; Management of severe alcohol withdrawal syndrome.
• Methods for implementation of best-evidence guidelines in critical care.

3. Lung host innate immunity in normal and mehcaniclaly ventilated adults

• Lung Microbiome study with Andew Fontenot and Sonia Flores
Co-Pilot VAP screening study  - CTSA and Accelr8